<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01981967</url>
  </required_header>
  <id_info>
    <org_study_id>JEC17</org_study_id>
    <secondary_id>U1111-1127-7052</secondary_id>
    <nct_id>NCT01981967</nct_id>
  </id_info>
  <brief_title>Post-licensure Safety Study of IMOJEV® in Thailand</brief_title>
  <official_title>Post-licensure, Phase IV, Safety Study of IMOJEV® in Thailand</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi Pasteur, a Sanofi Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to further characterize the safety profile of IMOJEV®.

      Primary Objective:

        -  To describe serious adverse events (SAEs, including adverse events of special interest
           [AESIs]) up to 60 days after administration of one dose of IMOJEV®.

      Secondary Objective:

        -  To describe Grade 3 (severe) systemic Adverse Events (AEs) up to 30 minutes after
           administration of one dose of IMOJEV®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants aged 1 year to less than 5 years will be randomized to receive one injection of
      IMOJEV® either as a primary vaccination or as a booster. Safety data will be collected for 60
      days after IMOJEV® vaccination. The duration of each subject's participation in the trial
      will be 60 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing a Grade 3 Immediate Systemic Adverse Events and Serious Adverse Events Following Any Vaccination With IMOJEV®</measure>
    <time_frame>30 minutes post-vaccination up to Day 60 post-vaccination</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Experiencing Serious Adverse Events By Age Following Any Vaccination With IMOJEV®</measure>
    <time_frame>Day O up to Day 60 post-vaccination</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events of Special Interest Within 60 Days Following Vaccination With IMOJEV®</measure>
    <time_frame>Day O up to Day 60 post-vaccination</time_frame>
    <description>Adverse Events of Special Interest (AESIs) included hypersensitivity/allergic reactions, neurological events (including febrile convulsions), and vaccine failure.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10000</enrollment>
  <condition>Japanese Encephalitis</condition>
  <arm_group>
    <arm_group_label>Primary Vaccination Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who never received a JE vaccine, or who received a single dose of inactivated JE vaccine, or whose JE vaccination history is unknown or not documented.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Booster Vaccination Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who received at least 2 doses of inactivated JE vaccine (at least 1 year earlier for the last dose), or received a single dose of IMOJEV®, THAIJEV®, or IMOJEV® MD as part of the routine vaccination schedule (i.e., outside of Study JEC17) at least 1 year earlier</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous.</description>
    <arm_group_label>Primary Vaccination Group</arm_group_label>
    <other_name>IMOJEV®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine</intervention_name>
    <description>0.5 mL, Subcutaneous.</description>
    <arm_group_label>Booster Vaccination Group</arm_group_label>
    <other_name>IMOJEV®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children requiring vaccination against Japanese encephalitis

          -  Children aged 9 months to less than 5 years on the day of inclusion

          -  In good general health at the time of inclusion

          -  Informed consent form has been signed and dated by the parent(s)/legal guardian(s)

          -  Subject and parent(s)/legal guardian(s) are able to attend the scheduled visit and any
             additional visits that may need to be done in case of an SAE (including AESI), and are
             able to comply with all trial procedures

          -  The subject's parent(s)/legal guardian(s) have a telephone number at which they can be
             contacted throughout the study

        Exclusion Criteria:

          -  Participation in another clinical trial investigating a vaccine, drug, medical device,
             or medical procedure in the 4 weeks preceding the vaccination

          -  Receipt of any vaccine in the 4 weeks preceding the study vaccination or planned
             receipt of any vaccine in the 4 weeks following the study vaccination

          -  Planned participation in another clinical trial during the present trial period

          -  Children previously vaccinated with the live attenuated Japanese encephalitis vaccine
             CD-JEVAX® (SA14-14-2 LAV)

          -  Contraindications to vaccination according to the IMOJEV® Summary of Product
             Characteristics (SmPC)

          -  Identified as a natural or adopted child of the Investigator or employee with direct
             involvement in the proposed study

          -  Children who received IMOJEV® as primary vaccination in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>9 Months</minimum_age>
    <maximum_age>4 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi Pasteur SA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bangkok</city>
        <zip>10400</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Khon Kaen</city>
        <zip>40002</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nakornnayok</city>
        <zip>26120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nonthaburi</city>
        <zip>11120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Songkla</city>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <link>
    <url>http://www.sanofipasteur.com</url>
  </link>
  <link>
    <url>http://www.sanofi.com</url>
  </link>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 5, 2013</study_first_submitted>
  <study_first_submitted_qc>November 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2013</study_first_posted>
  <results_first_submitted>March 31, 2016</results_first_submitted>
  <results_first_submitted_qc>March 31, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2016</results_first_posted>
  <last_update_submitted>March 31, 2016</last_update_submitted>
  <last_update_submitted_qc>March 31, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Japanese encephalitis</keyword>
  <keyword>IMOJEV®</keyword>
  <keyword>Japanese encephalitis chimeric virus vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Encephalitis</mesh_term>
    <mesh_term>Encephalitis, Japanese</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study participants were enrolled from 03 November 2013 to 08 February 2015 in 10 trial centers in Thailand.</recruitment_details>
      <pre_assignment_details>A total of 10,000 participants who met all of the inclusion and none of the exclusion criteria were vaccinated in this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Primary Vaccination Group</title>
          <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a primary vaccination.</description>
        </group>
        <group group_id="P2">
          <title>Booster Vaccination Group</title>
          <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a booster.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6851"/>
                <participants group_id="P2" count="3149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6851"/>
                <participants group_id="P2" count="3149"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Primary Vaccination Group</title>
          <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a primary vaccination.</description>
        </group>
        <group group_id="B2">
          <title>Booster Vaccination Group</title>
          <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a booster.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6851"/>
            <count group_id="B2" value="3149"/>
            <count group_id="B3" value="10000"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6851"/>
                    <measurement group_id="B2" value="3149"/>
                    <measurement group_id="B3" value="10000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.22" spread="0.486"/>
                    <measurement group_id="B2" value="3.60" spread="0.892"/>
                    <measurement group_id="B3" value="1.97" spread="1.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3321"/>
                    <measurement group_id="B2" value="1550"/>
                    <measurement group_id="B3" value="4871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3530"/>
                    <measurement group_id="B2" value="1599"/>
                    <measurement group_id="B3" value="5129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6851"/>
                    <measurement group_id="B2" value="3149"/>
                    <measurement group_id="B3" value="10000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing a Grade 3 Immediate Systemic Adverse Events and Serious Adverse Events Following Any Vaccination With IMOJEV®</title>
        <time_frame>30 minutes post-vaccination up to Day 60 post-vaccination</time_frame>
        <population>Safety outcome were assessed in subjects who had received the study vaccine, the Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Vaccination Group</title>
            <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Booster Vaccination Group</title>
            <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a booster.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing a Grade 3 Immediate Systemic Adverse Events and Serious Adverse Events Following Any Vaccination With IMOJEV®</title>
          <population>Safety outcome were assessed in subjects who had received the study vaccine, the Safety Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6851"/>
                <count group_id="O2" value="3149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade 3 immediate systemic adverse event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Seriuos adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Serious Adverse Events By Age Following Any Vaccination With IMOJEV®</title>
        <time_frame>Day O up to Day 60 post-vaccination</time_frame>
        <population>Safety outcome were assessed in subjects who had received the study vaccine, the Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Vaccination Group</title>
            <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Booster Vaccination Group</title>
            <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a booster.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Serious Adverse Events By Age Following Any Vaccination With IMOJEV®</title>
          <population>Safety outcome were assessed in subjects who had received the study vaccine, the Safety Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6851"/>
                <count group_id="O2" value="3149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SAEs in Subjects 9 to &lt;12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs in Subjects 1 to 2 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs in Subjects 2 to &lt;5 Years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Adverse Events of Special Interest Within 60 Days Following Vaccination With IMOJEV®</title>
        <description>Adverse Events of Special Interest (AESIs) included hypersensitivity/allergic reactions, neurological events (including febrile convulsions), and vaccine failure.</description>
        <time_frame>Day O up to Day 60 post-vaccination</time_frame>
        <population>Safety outcome were assessed in subjects who had received the study vaccine, the Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Primary Vaccination Group</title>
            <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a primary vaccination.</description>
          </group>
          <group group_id="O2">
            <title>Booster Vaccination Group</title>
            <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a booster.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events of Special Interest Within 60 Days Following Vaccination With IMOJEV®</title>
          <description>Adverse Events of Special Interest (AESIs) included hypersensitivity/allergic reactions, neurological events (including febrile convulsions), and vaccine failure.</description>
          <population>Safety outcome were assessed in subjects who had received the study vaccine, the Safety Analysis Set</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6851"/>
                <count group_id="O2" value="3149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Febrile convulsion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Convulsion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Epilepsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Frontal lobe epilepsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urticaria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected from Day 0 (post-vaccination) up to 60 post-vaccination</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Primary Vaccination Group</title>
          <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a primary vaccination.</description>
        </group>
        <group group_id="E2">
          <title>Booster Vaccination Group</title>
          <description>Children aged 9 months to less than 5 years who received one injection of IMOJEV® as a booster.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="204" subjects_at_risk="6851"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="6851"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Acute tonsillitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="6851"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Bronchitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Burkholderia pseudomallei infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Dengue fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Gastritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="29" subjects_affected="28" subjects_at_risk="6851"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Hand-foot-mouth disease</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6851"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6851"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="6851"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Scrotal abcess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Urinary track infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Viral rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="28" subjects_affected="25" subjects_at_risk="6851"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Frontal lobe epilepsy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6851"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6851"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5.00</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6851"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3149"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor must have the opportunity to review at least 60 days prior to submission for publication or presentation. If review indicates that potentially patentable subject matter would be disclosed, publication or public disclosure may be delayed for a maximum of an additional 60 days to allow for filing the necessary patent applications</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sanofi Pasteur Inc.</organization>
      <email>RegistryContactUs@sanofipasteur.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

